Reviews/SGLT2 Inhibitors/SGLT2 inhibitors slow kidney disease progression and reduce kidney failure risk
· SG-CK-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The evidence here says that this class of kidney drug both slows the decline of kidney function and lowers the chance of reaching kidney failure. A real-world comparison of patients with very heavy protein loss in the urine found fewer went on to dialysis or major kidney events on the drug [2], a dedicated kidney trial's main combined outcome was reduced [4], and a pooled look across two canagliflozin trials showed benefit on kidney failure needing treatment [22]. Supporting the progression limb, a biomarker study links part of the benefit to a slower fall in kidney function [1], and a canagliflozin analysis ties early drops in urine protein to better long-term kidney outcomes [20]. The effect points the same way across three different drugs in the class and in patients with and without diabetes. The panel landed high but short of the ceiling because the single strongest results in this particular corpus are a subgroup, a pooled analysis and a real-world comparison rather than the headline results of the dedicated trials themselves, which are present only inside review articles.
Hard-outcome primary data carry both limbs of the claim. A target-trial emulation in nephrotic-range proteinuria found lower ESKD risk (HR 0.73, 95% CI 0.62-0.85) and lower MAKE risk (HR 0.75, 95% CI 0.65-0.86) on SGLT2 inhibitors versus DPP4 inhibitors [2]. The DAPA-CKD primary composite of sustained eGFR decline, end-stage kidney disease, or kidney or cardiovascular death was reduced (HR 0.60, 95% CI 0.50-0.72 in the not-prescribed-MRA group) [4], and a CANVAS-plus-CREDENCE pooled analysis showed consistent benefit on kidney failure requiring therapy or doubling of serum creatinine [22]. The progression limb is further supported by mediation of empagliflozin's effect on chronic eGFR slope through reductions in albuminuria and uromodulin [1], and by the association between early albuminuria reduction and the primary kidney outcome (HR 0.71, 95% CI 0.67-0.76) in CREDENCE [20]. The direction is concordant across dapagliflozin, canagliflozin and empagliflozin in diabetic and non-diabetic CKD. The contested point: The division is over the grade of the strongest in-corpus evidence: the dedicated landmark trial primaries (DAPA-CKD, CREDENCE, EMPA-KIDNEY main reports) are present only inside study-type-excluded reviews, so the best standalone hard-outcome signals are a 5.3% subgroup [4], a pooled post hoc analysis [22], and a retrospective observational emulation [2]. Several supporting analyses ([5], [8], [20]) rest on albuminuria, a surrogate, and report association rather than a treatment effect on hard outcomes.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from SGLT2 Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The dedicated landmark trials (DAPA-CKD, CREDENCE, EMPA-KIDNEY main reports) are absent as primary papers — they survive only inside study-type-excluded reviews, so the strongest in-corpus hard-outcome evidence is a 5.3% subgroup [4], a pooled analysis [22], and an observational emulation [2] rather than a headline primary result.
[2] is a retrospective observational emulation; residual and unmeasured confounding survives propensity matching, and its authors themselves state dedicated randomized trials in nephrotic-range proteinuria remain necessary.
Where it remains uncertain. The dedicated trial primaries survive only inside excluded reviews, so the strongest standalone evidence here is a subgroup [4], a pooled analysis [22] and a retrospective emulation [2] whose own authors call for dedicated randomized trials [2].
Aleatory
The MRA-prescribed stratum in [4] rests on only 229 patients with a CI crossing 1, and [3] reports oxygenation in 20 patients, so chance variation is material at these sizes.
Epistemic
DAPA-CKD, CREDENCE and EMPA-KIDNEY main reports appear only inside study-type-excluded reviews ([7], [10]-[19], [23]), so their headline primary results cannot be scored directly.
Inferential
[5], [8] and [20] measure albuminuria or glycosuria, surrogates, and [20] reports association with the primary outcome rather than a randomized treatment effect on hard endpoints.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Confirms a beneficial effect on chronic eGFR slope — the progression limb.
“Exploratory mediation analyses suggest that reductions in albuminuria and UMOD accounted for 32% (15% to 52%) of the beneficial effect of empagliflozin on chronic eGFR slope.”
Panel auditInternal validity: high · scope of inference: Mechanistic effect of empagliflozin on urinary tubular/glomerular biomarkers in CKD patients of varying cause and diabetes status.Key limitations: biomarker surrogates, not clinical endpoints · mediation cannot confirm causal mediator
Hard kidney-failure endpoint (ESKD) reduced — supports the kidney-failure-risk limb.
“SGLT2i users had a lower risk of MAKE than DPP4i users (30.0% vs. 41.2%; HR 0.75, 95% CI 0.65-0.86), lower risk of ESKD (HR 0.73, 95% CI 0.62-0.85) and all-cause mortality (HR 0.71, 95% CI 0.55-0.91).”
Panel auditInternal validity: medium · scope of inference: Adults with T2DM and nephrotic-range proteinuria, an extreme high-risk phenotype; active comparator DPP4i.Key limitations: observational, residual confounding · very narrow phenotype · authors say dedicated RCTs still needed
DAPA-CKD primary composite (>=50% eGFR decline, ESKD, kidney/CV death) reduced — both progression and kidney failure.
“The effect of dapagliflozin on the primary outcome was consistent in participants prescribed (hazard ratio [HR] 0.76, 95% CI 0.40-1.47) and not prescribed (HR 0.60, 95% CI 0.50-0.72, P -interaction = 0.59) MRAs.”
Panel auditInternal validity: high · scope of inference: CKD patients with/without T2DM in DAPA-CKD, examining whether benefit holds among MRA users.Key limitations: tiny MRA subgroup (n=229) · subgroup CI crosses 1 in prescribed group
Results concern renal oxygenation (R2*) imaging, not progression or kidney-failure endpoints; the slowing of progression is cited only as background.
Panel auditInternal validity: low · scope of inference: Whether dapagliflozin alters BOLD-MRI renal oxygenation in CKD patients, more so in nondiabetics.Key limitations: n=20, surrogate imaging endpoint · short 12-week follow-up · authors call for confirmation
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent primary analyses carry both the progression and kidney-failure limbs with concordant direction, held just off the ceiling because the in-corpus hard-outcome evidence is a subgroup, a pooled analysis and an observational emulation rather than the dedicated trial primaries.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Dedicated trial primaries absent as primary papers. The strongest hard-outcome evidence in this corpus is a subgroup, a pooled analysis and an observational emulation; the headline randomized primary results are only described inside excluded reviews. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include the dedicated DAPA-CKD, CREDENCE and EMPA-KIDNEY primary trial reports as scorable primary papers.
Open question: Do SGLT2 inhibitors reduce hard kidney-failure endpoints in patients with nephrotic-range proteinuria when tested in a randomized design? Why it is still open: The only in-corpus evidence in this phenotype is the retrospective emulation [2], whose authors explicitly state dedicated randomized trials remain necessary.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19